^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
CELLSEARCH®

Company:
Menarini
Type:
FDA Approved
Evidence Level:
Sensitive: C3 – Early Trials

[PD-L1 expression-Non Small Cell Lung Cancer-PD-L1 inhibitor]

Title:
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Published date:
03/16/2021
Excerpt:
Thirty-nine patients treated with anti-PD-1/PD-L1 agents as second- or third-line therapy were enrolled...Patients were divided into 3 groups: no CTC detectable (CTCnull, n = 15), PD-L1 positive CTC (CTCpos, n = 13), and PD-L1 negative CTC (CTCneg, n = 11)....PD-L1 expression on CTCs is a promising biomarker in patients with NSCLC treated with ICIs.
DOI:
10.1016/j.cllc.2021.03.005
Evidence Level:
Sensitive: C3 – Early Trials

[PD-L1 expression-Non Small Cell Lung Cancer-PD1 inhibitor]

Title:
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Published date:
03/16/2021
Excerpt:
Thirty-nine patients treated with anti-PD-1/PD-L1 agents as second- or third-line therapy were enrolled...Patients were divided into 3 groups: no CTC detectable (CTCnull, n = 15), PD-L1 positive CTC (CTCpos, n = 13), and PD-L1 negative CTC (CTCneg, n = 11)....PD-L1 expression on CTCs is a promising biomarker in patients with NSCLC treated with ICIs.
DOI:
10.1016/j.cllc.2021.03.005